Justin B. Klee, Co-Chief Executive Officer at Amylyx Pharmaceuticals, Inc. (AMLX), sold 59,750 shares at $14.37 ($859K) on 2025-09-30, disclosed to the SEC on 2025-10-02.
Open-market sale of $859k AMLX by Co-Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.37 | 29,775 | $428K | 49.8% |
| 2 | $14.37 | 29,775 | $428K | 49.8% |
| 3 | $15.01 | 200 | $3K | 0.3% |
| Total | $14.37 avg | 59,750 | $859K | 100% |
| Filing → |
| AMLX | SELL | 2026-02-04 | $228K | — | Filing → |
| AMLX | SELL | 2026-01-20 | $3.8M | — | Filing → |
| AMLX | SELL | 2026-01-08 | $86K | — | Filing → |